Shares of Novo Nordisk nosedivedas much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to placebo.
This is breaking news. Please refresh for updates.
About The Author
Shares of Novo Nordisk nosedivedas much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to placebo.
This is breaking news. Please refresh for updates.
